Key result
Relying on short-term heart failure trials may exaggerate effects and fail to accurately predict long-term benefits and risks in patients with chronic disease.
Answers are grounded in this paper and cite their sources.
This editorial cautions against relying on short-term heart failure trials to predict long-term benefits and risks.
A new drug for heart failure is typically evaluated in a trial of 2000-4000 patients with stable chronic heart failure (designated as “chrHF”) who are randomized to placebo or active treatment, which is added to all established treatments for the disease. Patients are generally followed for a median of 10-28 months for cardiovascular death or hospitalization for heart failure and for long-term safety.
No takes yet. Share an insight, caveat, or question.
Milton Packer (2023) conducted an editorial in stable chronic heart failure. Relying on short-term heart failure trials may exaggerate effects and fail to accurately predict long-term benefits and risks in patients with chronic disease.
Synapse has enriched 10 related papers. Consider them for comparative context: